Microbot Medical Inc. (MBOT) #Trading Down 2.3% Following #Insider Selling

Shares of Microbot Medical Inc. (NASDAQ:MBOT) were down 2.3% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $1.30 and last traded at $1.30. Approximately 705,801 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 1,558,170 shares. The stock had previously closed at $1.33.

Specifically, Director Yoseph Bornstein sold 45,610 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $1.01, for a total transaction of $46,066.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Moshe Shoham sold 33,700 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $1.50, for a total transaction of $50,550.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 324,310 shares of company stock valued at $405,396. 31.83% of the stock is owned by corporate insiders.

The company’s 50 day moving average price is $1.18 and its 200 day moving average price is $2.48. The firm’s market capitalization is $59.90 million.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.44. Equities analysts predict that Microbot Medical Inc. will post ($25.02) EPS for the current year.

A hedge fund recently raised its stake in Microbot Medical stock. Vanguard Group Inc. increased its stake in Microbot Medical Inc. (NASDAQ:MBOT) by 252.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 159,992 shares of the biotechnology company’s stock after purchasing an additional 114,561 shares during the period. Vanguard Group Inc. owned 0.43% of Microbot Medical worth $228,000 as of its most recent filing with the Securities & Exchange Commission. 4.72% of the stock is owned by institutional investors.

Specifically, Director Yoseph Bornstein sold 45,610 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $1.01, for a total transaction of $46,066.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Moshe Shoham sold 33,700 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $1.50, for a total transaction of $50,550.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 324,310 shares of company stock valued at $405,396. 31.83% of the stock is owned by corporate insiders.

The company’s 50 day moving average price is $1.18 and its 200 day moving average price is $2.48. The firm’s market capitalization is $59.90 million.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.44. Equities analysts predict that Microbot Medical Inc. will post ($25.02) EPS for the current year.

A hedge fund recently raised its stake in Microbot Medical stock. Vanguard Group Inc. increased its stake in Microbot Medical Inc. (NASDAQ:MBOT) by 252.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 159,992 shares of the biotechnology company’s stock after purchasing an additional 114,561 shares during the period. Vanguard Group Inc. owned 0.43% of Microbot Medical worth $228,000 as of its most recent filing with the Securities & Exchange Commission. 4.72% of the stock is owned by institutional investors.

Source:https://ledgergazette.com/2017/10/13/microbot-medical-inc-mbot-trading-down-2-3-following-insider-selling.html

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 67 = 76